Skip to main content
SpringerLink
Log in

Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy

  • LUNG CANCER
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Lung cancer (LC) is the leading cause of cancer mortality. PATP was provided in experimental trials to decrease the venous thromboembolism (VTE), with ultimate aim to improve overall survival (OS). We undertook an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the impact of PATP with LMWHs on OS and VTE in patients with LC. 5443 patients with LC from nine RCTs were included. The pooled hazard ratio (HR) for OS was 1.02 (95% CI 0.83 to 1.26; P = 0.83) and for progression or metastasis-free survival was 1.03 (95% CI 0.86 to 1.24; P = 0.74). The pooled risk ratio (RR) for VTE was 0.54 (95% CI 0.43 to 0.69; P < 0.00001) and the risk difference (RD) was—0.03 (− 0.05 to − 0.02; P < 0.00001). Our analysis showed no survival advantage with the addition of PATP with LMWHs to standard chemotherapy in patients with LC, regardless of histology or stages of small cell LC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917

    Article  CAS  Google Scholar 

  2. Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275

    Article  Google Scholar 

  3. Streiff MB (2013) Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients. Clin adv Hematol Oncol 11(6):349–357

    PubMed  Google Scholar 

  4. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634

    Article  CAS  Google Scholar 

  5. Thein KZ, Yeung SJ, Oo TH (2018) Primary thrombopylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials (RCTs). Asia Pac J Clin Oncol 14(3):210–216

    Article  Google Scholar 

  6. MoherLiberatiTetzlaffAltman DAJDG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269

    Article  Google Scholar 

  7. Higgins JP (2008) Cochrane handbook for systematic reviews of interventions version 5.1.0 the cochrane collaboration. https://handbook-5-1.cochrane.org/. Accessed 25 Feb 2020.

  8. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical Res ed) 327(7414):557–560

    Article  Google Scholar 

  9. Page MJ, McKenzie JE, Higgins JPT (2018) Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review. BMJ Open 8(3):e019703

    Article  Google Scholar 

  10. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2(8):1266–1271

    Article  CAS  Google Scholar 

  11. Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, Wallberg M, Falkmer U, Verma S, Belting M (2018) Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann oncol : off J Eur Soc Med Oncol 29(2):398–404

    Article  CAS  Google Scholar 

  12. Groen HJM, van der Heijden E, Klinkenberg TJ, Biesma B, Aerts J, Verhagen A, Kloosterziel C, Pieterman R, van den Borne B, Smit HJM, Hoekstra O, Schramel F, van der Noort V, van Tinteren H, Smit EF, Dingemans AC (2019) Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. Br J Cancer 121:372–377

    Article  CAS  Google Scholar 

  13. Lecumberri R, Lopez Vivanco G, Font A, Gonzalez Billalabeitia E, Gurpide A, Gomez Codina J, Isla D, Galan A, Bover I, Domine M, Vicente V, Rosell R, Rocha E (2013) Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res 132(6):666–670

    Article  CAS  Google Scholar 

  14. Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Woll PJ, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G (2016) Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol 34(5):488–494

    Article  CAS  Google Scholar 

  15. Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P (2018) Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. The European respiratory journal 52 (4).

    Article  Google Scholar 

  16. Agnelli G1, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943–949

    Article  CAS  Google Scholar 

  17. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601–609

    Article  CAS  Google Scholar 

  18. Haas SK1, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF et al (2012) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 18(2):159–165

    Article  CAS  Google Scholar 

  19. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Petites Cell Group. Cancer 74(1):38–45

    CAS  PubMed  Google Scholar 

  20. Hejna M, Raderer M, Zielinski CC (1999) Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91(1):22–36

    Article  CAS  Google Scholar 

  21. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907

    Article  CAS  Google Scholar 

  22. Kuderer NM, Poniewierski MS, Culakova E, Lyman GH, Khorana AA, Pabinger I, Agnelli G, Liebman HA, Vicaut E, Meyer G, Shepherd FA (2018) Predictors of venous thromboembolism and early mortality in lung cancer: Results from a global prospective study (CANTARISK). Oncologist 23(2):247–255

    Article  Google Scholar 

  23. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A (2020) Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):495–520

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA

    Kyaw Zin Thein

  2. Department of Hematology/Oncology, Texas Tech University Health Sciences Center, Lubbock, USA

    Donald Paul Quick & Lukman Tijani

  3. Joe Arrington Cancer Research and Treatment Center, Lubbock, USA

    Donald Paul Quick

  4. Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK

    Thura Win Htut

  5. Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Thein Hlaing Oo

Authors
  1. Kyaw Zin Thein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Paul Quick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thura Win Htut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lukman Tijani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thein Hlaing Oo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have equally contributed to the manuscript.

Corresponding author

Correspondence to Thein Hlaing Oo.

Ethics declarations

Conflict of interest

Kyaw Z Thein, Donald P. Quick, Lukman Tijani and Thura W Htut declare no conflict of interest. Thein H Oo received honoraria from Medical Education Speakers Network, served as a co-investigator for Janssen and Janssen and on Advisory Board for Bristol-Myers Squibb, not related to this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thein, K.Z., Quick, D.P., Htut, T.W. et al. Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy. Lung 198, 575–579 (2020). https://doi.org/10.1007/s00408-020-00347-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-020-00347-0

Keywords

Search

Navigation